{{Rsnum
|rsid=3814113
|Chromosome=9
|position=16915023
|Orientation=plus
|GMAF=0.3953
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 12.4 | 49.6 | 38.1
| HCB | 9.6 | 34.1 | 56.3
| JPT | 2.7 | 42.9 | 54.5
| YRI | 47.9 | 39.0 | 13.0
| ASW | 33.3 | 49.1 | 17.5
| CHB | 9.6 | 34.1 | 56.3
| CHD | 10.3 | 35.5 | 54.2
| GIH | 11.9 | 51.5 | 36.6
| LWK | 47.3 | 39.1 | 13.6
| MEX | 39.7 | 48.3 | 12.1
| MKK | 39.1 | 44.2 | 16.7
| TSI | 11.8 | 37.3 | 51.0
| HapMapRevision=28
}}[[rs3814113]] is a SNP ~44kb upstream of the [[BNC2]] gene on chromosome 9.

A very large study of multiple populations, ultimately totaling almost 10,000 [[ovarian cancer]] patients and an equal number of matched controls, concluded that the per allele odds ratio associated with the [[rs3814113]](C) allele was 0.79 (CI: 0.75-0.84, p=2.5x10e-17). This association held in 5 types of (ethnic) populations studied, and was strongest in association with serous ovarian cancers.{{PMID|19648919|OA=1
}}

An independent study of 10,000+ BRCA1 mutation carriers and almost 6,000 BRCA2 mutation carriers provided confirmation for the original report, finding the [[rs3813113]](C) allele to be associated with a reduced risk of [[ovarian cancer]] among BRCA1 mutation carriers (per-allele hazard ratio 0.78, CI: 0.72 - 0.85, p = 4.8 × 10e-9) and BRCA2 mutation carriers (hazard ratio 0.78, CI: 0.67 - 0.90, p = 5.5 × 10e-4). [[rs3814113]] was not associated with higher (or lower) breast cancer risk among either BRCA1 or BRCA2 mutation carriers. Overall, BRCA1 mutation carriers with a [[rs3814113]](T;T) genotype were predicted to have an ovarian cancer risk to age 80 years of 48%, compared to a risk of 33% for [[rs3814113]](C;C) genotypes.{{PMID|21169536|OA=1
}}

{{PMID|21642636}} Ovarian cancer-associated polymorphisms in the BNC2 gene among women with endometriosis.

{{PMID|22235027|OA=1
}} Evaluation of microRNA expression profiles and their associations with risk alleles in lymphoblastoid cell lines of familial ovarian cancer.

{{GET Evidence
|impact=pathogenic
|qualified_impact=Insufficiently evaluated pathogenic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs3814113
|overall_frequency_n=58
|overall_frequency_d=126
|overall_frequency=0.460317
|n_genomes=34
|n_genomes_annotated=0
|n_haplomes=48
|n_articles=0
|n_articles_annotated=0
|in_gwas=Y
|autoscore=1
|webscore=N
}}

{{PMID Auto GWAS
  |PMID=23535730
  |Trait=Ovarian cancer
  |Title=GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer.
  |RiskAllele=
  |Pval=4E-32
  |OR=1.28
  |ORtxt=[1.23-1.33]
  |OA=1
}}

{{PMID Auto GWAS
  |PMID=23544013
  |Trait=Ovarian cancer in BRCA1 mutation carriers
  |Title=Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk.
  |RiskAllele=A
  |Pval=6E-11
  |OR=1.30
  |ORtxt=[1.2-1.41]
  |OA=1
}}

{{PMID Auto
|PMID=23133607
|Title=Associations between gene expression variations and ovarian cancer risk alleles identified from genome wide association studies.
|OA=1
}}

{{PMID Auto
|PMID=25173882
|Title=Replication Study for the Association of Seven Genome- Gwas-Identified Loci With Susceptibility to Ovarian Cancer in the Polish Population
}}
{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}